Wells Fargo’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
Other funds holding DNLI
Wells Fargo's DNLI Position: Q2 2026 in Review
Wells Fargo increased its Denali Therapeutics (DNLI) stake by 76% in Q2 2026, buying an estimated $1.69M and bringing the position to 189,865 shares worth $4.88M. The position accounts for ﹤0.01% of the portfolio, ranked #2869.
Wells Fargo first reported a position in DNLI in Q4 2017 and has held it in 35 quarters since. The position peaked at $11.6M in Q2 2021. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Wells Fargo held 189,865 shares of Denali Therapeutics worth $4.88M as of Q2 2026.
- Wells Fargo bought 82,208 Denali Therapeutics shares in Q2 2026, an estimated $1.69M.
- Denali Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2869 holding.
- Wells Fargo first reported a position in Denali Therapeutics in Q4 2017 and has held it in 35 quarters since.
- Wells Fargo's Denali Therapeutics position peaked at $11.6M in Q2 2021.
- 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.